# Safety and Blood Level Study of Unit Dose Budesonide

> **NCT00627679** · PHASE1 · COMPLETED · sponsor: **Allergan** · enrollment: 16 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Budesonide Inhalation Suspension
- **DRUG:** MAP0010 low dose
- **DRUG:** MAP0010 intermediate dose
- **DRUG:** MAP0010 high dose

## Key facts

- **NCT ID:** NCT00627679
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2005-12
- **Final completion:** 2006-05
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-01-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00627679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00627679, "Safety and Blood Level Study of Unit Dose Budesonide". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00627679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*